BLU Bellus Health Inc
BELLUS Health is focused on developing drugs for rare diseases, starting with conditions that affect the kidneys. The lead program KIACTAâ?¢, a novel drug candidate, is in data review after announcing on June 20, 2016 top-line results from its Phase 3 study for the treatment of AA amyloidosis, a rare disease resulting in renal dysfunction that often leads to dialysis and death. BELLUS Health is partnered with global private equity firm Auven Therapeutics for the development of KIACTAâ?¢. KIACTAâ?¢ is also being developed as a treatment in a second indication called sarcoidosis, a rare, potentially fatal inflammatory condition that affects the lungs. An investigational new drug application (IND) for a Phase 2/3 clinical study is expected to be filed with the U.S. Food and Drug Administration in 2016. In addition, BELLUS Health is developing Shigamabâ?¢, an antibody treatment for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli (sHUS). sHUS often leads to dialysis, chronic kidney disease and in some cases death, particularly in children. Shigamabâ?¢ pre-clinical studies for the treatment of sHUS are currently underway. BELLUS Healthâ??s pipeline also includes a research-stage project for the treatment of AL amyloidosis, a rare disease in which amyloid protein builds up and causes dysfunction in various parts of the body.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A
Frequently Asked Questions
What is Market Cap of Bellus Health Inc?
What is the 52-week high for Bellus Health Inc?
What is the 52-week low for Bellus Health Inc?
What is Bellus Health Inc stock price today?
What is the PE ratio of Bellus Health Inc?
What is the Price-to-Book ratio of Bellus Health Inc?
What is Bellus Health Inc's EBITDA?
What is the 50-day moving average of Bellus Health Inc?